Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of ($0.41), $0.03 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.01 million versus the consensus estimate of $5.12 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.